Concept

Trial Results

ASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor / TRITON: Tremelimumab Plus Durvalumab and Chemotherapy

"In this phase 2b trial (NCT06008093), researchers randomly assigned 84 patients to receive T+D+CT (n=41) or P+CT (n=43). According to the presentation abstract, patients in the first group received 75 mg tremelimumab, 1500 mg durvalumab and pemetrexed-platinum chemotherapy every 3 weeks for 4 cycles, then maintenance durvalumab and pemetrexed every 4 weeks until disease progression; additional doses of tremelimumab were given at week 16 and optionally at month 24. The control group received 200 mg pembrolizumab plus chemotherapy every 3 weeks until disease progression, for up to 24 months. The confirmed ORR was 39.0% with T+D+CT and 34.9% with P+CT. The median duration of response was not reached and 6.4 months, respectively. One hundred percent of responders in the T+D+CT arm were still in response at 6 months, compared to 58.3% of patients in the P+CT group."

Related Ideas

  • Pumitamig TherapyASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · ROSETTA Lung-02: Pumitamig
  • Trial DesignASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · ROSETTA Lung-02: Pumitamig
  • Response RatesASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · ROSETTA Lung-02: Pumitamig
  • Study DesignASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib
  • Safety SignalsASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · ROSETTA Lung-02: Pumitamig
  • Trial EfficacyASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CROWN: 7-Year Update for Lorlatinib
  • Survival OutcomesASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib
  • Safety ProfileASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib
Trial Results | ASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor | Bifalgorithm | Bifalgorithm